News & Press

The First FDA Approved Treatment for Metastatic Uveal Melanoma: What It Means for the OM Community

February 11, 2022

On January 26, 2022, the U.S. Food and Drug Administration announced the approval of KIMMTRAK (tebentafusp-tebn), the first and only FDA-approved treatment for metastatic uveal melanoma, developed by Immunocore. The approval follows Phase III clinical …

Advocating Through Research Review Processes

February 11, 2022

Guest blog post by Kristin R. McJunkins, Stage III melanoma survivor and advocate: In 2008 when I was 38 years old, I was diagnosed with Stage IIIa cutaneous melanoma. After two surgeries, which included some lymph node removal, it was determined that …

A Monumental First Step in Uveal Melanoma

February 9, 2022

Guest blog post by Keith T. Flaherty, MD, Associate Professor of Medicine at Harvard Medical School, Director of Developmental Therapeutics at Massachusetts General Hospital Cancer Center and Co-Chair of the MRF’s CURE OM Scientific Steering Committee: …

Scientific Peer Review of Congressionally Directed Medical Research Programs’ Melanoma Research Program for the Department of Defense

January 21, 2022

The MRF is proud to share the following press release from the Congressionally Directed Medical Research Program announcing MRF Board Chair (and melanoma survivor) Doug Brodman’s participation in the review of applications for a $30 million appropriati …

25th Anniversary: A Mouse Model in BRAF-induced Melanoma

December 22, 2021

Guest blog post by Martin McMahon, PhD, Senior Director of Preclinical Research, Principal Investigator at Huntsman Cancer Institute. Dr. McMahon received the Diana Ashby Senior Investigator Award (in memory of Linda A. Transou) in January 2006 and ser …